Editorial, Res J Clin Pediatr Vol: 9 Issue: 1
Pediatric Tuberculosis: Diagnostic Advances and Treatment Challenges
Sanjana Desai*
Pediatric Infectious Diseases, BJ Medical College, Ahmedabad, India
- *Corresponding Author:
- Sanjana Desai
Pediatric Infectious Diseases, BJ Medical College, Ahmedabad, India
E-mail: sanjana.desai@bjmc.edu.in
Received: 01-March-2025, Manuscript No RJCP-25-169432; Editor assigned: 4-March-2025, Pre-QC No. RJCP-25-169432 (PQ); Reviewed: 20-March-2025, QC No RJCP-25-169432; Revised: 26-March-2025, Manuscript No. RJCP-25- 169432 (R); Published: 30-March-2025, DOI: 10.4172/rjcp.1000166
Citation: Sanjana D (2025) Pediatric Tuberculosis: Diagnostic Advances and Treatment Challenges. Res J Clin Pediatr 14:166
Introduction
Tuberculosis (TB) in children remains a diagnostic challenge due to its paucibacillary nature and nonspecific clinical presentations. India accounts for nearly a third of the global pediatric TB burden, demanding focused attention on early detection and treatment.
Diagnostic Innovations
Traditional diagnostic methods like Mantoux test and chest X-rays lack specificity in pediatric TB [1]. CBNAAT (GeneXpert) has improved bacteriological confirmation rates, especially for extrapulmonary cases [2].
Newer tools like TrueNat and stool-based molecular tests offer hope for non-invasive testing [3]. Despite these advances, underdiagnosis continues, especially in children under five and in rural areas [4].
Treatment and Drug Resistance Concerns
First-line therapy remains a 6-month regimen using HRZE, but the emergence of MDR-TB in children poses significant challenges [5]. The use of child-friendly drug formulations and adherence support through DOTS-Plus strategies are critical.
BCG vaccine, though not fully protective, reduces severe TB manifestations. Ongoing trials with newer vaccines and shorter regimens may revolutionize future pediatric TB care.